INTRODUCTION
Inhibition of T cell activation is essential in the treatment of certain autoimmune diseases and in the prevention of graft-versus-host disease (GVHD) that accompanies hematopoietic stem cell transplantation. Mycophenolate mofetil (MMF/Cellcept), has been used in combination with other immunosuppressive drugs to treat GVHD and is a potent, selective and reversible inhibitor of the type II isoform of inosine monophosphate dehydrogenase, an enzyme involved in the de novo biosynthesis of guanine nucleotides. [1] [2] Mycophenolic acid (MPA), the active ingredient in MMF, depletes guanine nucleotides in T and B lymphocytes, resulting in inhibition of lymphocyte proliferation and suppression of cell-mediated immune responses and antibody production. [2] [3] The depletion of guanine nucleotides by MPA has also been shown by ourselves and others to inhibit the synthesis of ribosomal RNA (rRNA), [4] [5] although the mechanism underlying this effect has not been identified.
Transcription initiation factor I (TIF-IA), a key intermediate in the overall regulation of rRNA synthesis, [6] [7] is ubiquitously expressed in mammalian cells [8] [9] [10] and is required to recruit Pol HDM2, [23] [24] while the p42 isoform has been regarded as a tumor suppressor [25] [26] . In addition to ErbB3, the long form of Ebp1 interacts with a variety of other proteins relevant to cell proliferation including nucleophosmin and Akt. [27] [28] A specific role for Ebp1 as a regulator of rRNA synthesis has not been established, although it has been postulated to interfere with rRNA processing and ribosome biogenesis when localized in the nucleolus. 17 After initially noting that the TIF-IA sequence contained a consensus binding site for GTP, we asked 1) whether the binding of GTP was required for TIF-IA function in regulating rRNA synthesis in T lymphocytes and 2) if so, whether the binding of GTP resulted in additional protein-protein interactions of TIF-IA. The results of these studies demonstrate that the GTP is required for the interaction of TIF-IA with Ebp1 and that both are important contributors to the regulation of rRNA synthesis and to T lymphocyte activation. These data provide both a further explanation of the mechanism of action of MPA and an additional target that might be exploited to enhance its immunosuppressive activity.
METHODS

Human patient samples and primary T cell isolation and culture
After informed consent under Stanford IRB protocol number 14734, peripheral blood mononuclear cells (PBMCs) were obtained from patients with systemic lupus erythematosus through the Stanford Immunologic and Rheumatic Diseases
Registry and Biospecimen Repository. Viable PBMCs were isolated using Ficoll
Hypaque separation and cryopreserved until use. All patients were on MMF at a stable dose for more than 3 months at the time blood was obtained.
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For longer term cultures, PBMCs were cultured in 96-well round-bottom plates pre-coated with 1 μg/ml anti-CD3 (OKT3, BioLegend) and 1 μg/ml anti-CD28 (CD28.2, BioLegend) in RPMI medium supplemented with 2% human AB serum (Cellgro), 100 U/ml penicillin, and 100 μg/ml streptomycin. Cells were first cultured for five days to generate CD3+ T-cells. MPA was added at that time point, referred to as "Day 0" of the experiment.
Synthetic small interfering RNA (siRNA) oligonucleotides
The siGENOME SMARTpool for si-RNAs was purchased from Thermo Scientific (Lafayette, CO). Scrambled control RNA (SCR) was used as a control. The target sequences for siRNAs are shown in the Table S1 . In each instance, protein expression was verified as being less than 50% of the control value.
Cells were washed and incubated in phosphate-free DMEM (Gibco) supplemented with 10% FBS for 2 hours followed by one hour labeling with 0.5 mCi [
32 P] orthophosphate (Perkin Elmer). Total RNA was extracted with Trizol (Life Technologies) following the manufacture's protocol. Equal amounts of RNA (10 μg) were separated on a 1.2% MOPS formaldehyde gel.
The gel was dried and visualized by autoradiography.
IL-2 measurements
Measurement of IL-2 production in T cells was performed with the ELISA kit from BioLegend (San Diego, CA) following the manufacture's instructions. CD3+ T-cells were seeded in IL-2
antibody-coated 96-well plates. A biotin-conjugated anti-human IL-2 detection antibody and avidin-conjugated horseradish peroxidase were added and absorbance is read at 450 nm.
Statistical Analysis
Where indicated, results were compared using the unpaired Student t test with values obtained from at least three independent experiments. P < 0.05 was considered significant.
RESULTS
MPA inhibits rRNA synthesis and cell proliferation in T cells through TIF-IA
We employed both cultured primary human T cells and a Jurkat T cell line to elucidate the relationship between MPA and rRNA synthesis. MPA suppresses rRNA synthesis in primary T cells as measured by the level of 5'ETS pre-rRNA and Pol I recruitment to rDNA ( Figure 1A , left and middle). Cell proliferation as determined by MTS and CFSE assays is also reduced ( Figure 1A , right and supplemental Figure 1C ). MPA also inhibits the expression of proliferating cell nuclear antigen (PCNA) protein, with a corresponding increase in p-H2AX and p53 levels Figure 3C ). We conclude from these data that TIF-IA is a GTP binding protein. As shown in Figure 3D and supplemental Figure 3D 
TIF-IA is a cofactor for Ebp1-regulated PCNA transcription
The above results suggest that MPA suppresses T cell proliferation by decreasing the binding of GTP to TIF-IA, ultimately resulting in an increase in p53 and a decrease in PCNA expression. In looking for potential intermediates in this pathway, we examined the role of Ebp1, a negative regulator of p53 23 that is increased in expression in proliferating T cells (Figure 2A ).
Overexpression of Ebp1 in Jurkat T cells decreased p53 expression and increased PCNA protein levels (supplemental Figure 4A , left), as has been noted previously 23 . Ebp1 overexpression also enhanced cell proliferation and colony formation (supplemental Figure 4A , right) as well as Figure 4A , middle). In contrast, reducing Ebp1 expression increased p53 expression while concomitantly decreasing PCNA mRNA and protein levels, and cell proliferation ( Figure 4A ). Comparing MEF Ebp1 -/-to Ebp1 WT cells, 35 it is apparent that the absence of Ebp1 expression is associated with elevated p53 protein levels and decreased expression of PCNA at both the mRNA and protein levels ( Figure 4B , left and middle).
Overexpression of Ebp1 in MEF Ebp1-/-cells, which grow more poorly than their WT counterparts ( Figure 4B , right), enhances both PCNA expression and cell proliferation (supplemental Figure 4B ).
Ebp1 binds to TIF-IA in both primary and Jurkat T cells ( Figure 4C ). This interaction was confirmed by immunoprecipitation using recombinant GST-TIF-IA and endogenous Ebp1 or exogenous GFP-Ebp1 expressed in 293 T cells (supplemental Figure 4C) . The Ebp1-TIF-IA interaction is markedly enhanced in T cells stimulated with anti-CD3/CD28 antibodies ( Figure   4D , left and right) and is associated with increases in PCNA mRNA and protein levels ( Figure   4D , left and middle), suggesting that the interaction of TIF-IA with Ebp1 is important in regulating PCNA transcription through p53. Indeed, a reduction of either TIF-IA or Ebp1 protein effectively increased p53 protein expression and inhibited PCNA transcription and cell proliferation ( Figure 4E ), while knocking down both Ebp1 and TIF-IA significantly enhanced the effects of siEbp1 alone ( Figure 4E ). In contrast, co-overexpression of Ebp1 and TIF-IA markedly decreased p53 and enhanced PCNA and cell proliferation (supplemental Figure 4D ).
Moreover, reducing the expression of TIF-IA diminished the effects of Ebp1 on both p53 expression and PCNA transcription and cell proliferation ( Figure 4F ). These data demonstrate the relevance of the TIF-IA-Ebp1 interaction for the regulation of PCNA expression and cell proliferation and also suggest a role for p53 as an intermediary in these effects. and retained more TIF-IA in the nucleolus ( Figure 7B ). These data suggest that the and Sotrastaurin as opposed to either drug alone markedly reduced the production of interleukin-2 by primary T cells ( Figure 7G ). In summary, inhibiting Ebp1 phosphorylation at S360 with an
inhibitor of PKCδ appears to be an effective mechanism for inhibiting T cell activation and proliferation and is complementary to the inhibitory effects of MPA on rRNA synthesis.
DISCUSSION
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The synthesis of rRNA, an essential component of ribosome biogenesis, is regulated in a growth-dependent manner that is evolutionarily conserved. TIF-IA is one of the critical components of the pre-initiation complex that is required for the transcription of rDNA into rRNA and is thus a key target for growth-regulated signaling. 37 Although it has been recognized that Figure   7H ).
For interaction, the fact that the S360D mutant largely abrogates Sotrastaurin's ability to inhibit rRNA synthesis supports specificity for S360 phosphorylation as the primary mechanism by which the drug is having its effect. We conclude that the Ebp1/TIF-IA interaction is also dependent on S360 phosphorylation.
Over the past two decades, the success of various forms of transplantation has been tightly linked to the development of new approaches to immunosuppression. 
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